BG505 MD39.3 HIV Trimer mRNA Vaccine

· National Institute of Allergy and Infectious Diseases (NIAID)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BG505 MD39.3 HIV Trimer mRNA Vaccine, covering 2024-10-31 to 2024-10-31. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants [Phase 1]

See pricing